|
|
CAN
|
No CAN
|
p
value
|
| Recipients’ age, mean±SD, in years |
27.6±8.0 |
28.1±9.5 |
0.73 |
| Recipients’ sex, n(%) |
|
|
|
| Male |
39 (90.9%) |
91 (74.4%) |
0.02 |
| Female |
4 (9.5%) |
31 (25.1%) |
|
| Donors’ sex, n(%) |
|
|
|
| Male |
39 (90.9%) |
91 (74.4%) |
0.72 |
| Female |
4 (9.5%) |
31 (25.1%) |
|
| Human leukocyte antigen (HLA) match, n(%) |
|
|
|
| >3 antigen |
19(45.2%) |
70 (57.4%) |
0.17 |
| ≤ 3 antigen |
23(54.8%) |
52 (42.3%) |
|
| Antithymocyte globulin (ATG), n(%) |
3 (7.1%) |
9 (7.4%) |
|
| Immunosuppressive regimen, n(%) |
|
|
|
| Pred, CyA, Aza |
40 (95.2%) |
113 (92.6%) |
0.55 |
| Pred, CyA, MMF |
2 (4.8%) |
9 (7.4%) |
|
| Donors’ creatinine clearance (ml/min) |
121.8878±21.1883 |
120.9445±20.0328 |
0.72 |
| Delayed graft function (DGF), n(%) |
4 (9.5%) |
7 (5.7%) |
0.39 |
| Early graft function, n(%) |
38 (90.5%) |
115 (94.3%) |
0.92 |
| ATG for induction/DGF, n(%) |
3 (7.1%) |
9 (7.4%) |
|
| Secondary surgery, n(%) |
6 (11.9%) |
7 (5.7%) |
0.19 |
| Acute tubular necrosis on early biopsy, n(%) |
9 (21.4%) |
26 (21.3%) |
0.98 |
| Dialysis required in early period, n(%) |
3 (7.1%) |
8 (6.6%) |
0.96 |
| Acute cellular rejection, n(%) |
6 (14.3%) |
18 (14.4%) |
0.94 |
| Acute vascular rejection, n(%) |
6 (14.3%) |
8 (6.6%) |
0.12 |
| Cyclosporin A (CyA) toxicity, n(%) |
5 (11.9%) |
17 (13.9%) |
0.73 |
| AUC of CyA (Mean±SD) |
6293±2431 |
6716±2012 |
0.28 |
| Cytomegalovirus infection, n(%) |
5 (13.2%) |
1 (0.8%) |
0.001 |
| Polyoma virus infection, n(%) |
6 (14.3%) |
1 (0.8%) |
0.0001 |
| Urinary tract infections, n(%) |
10 (23.8%) |
24 (19.7%) |
0.56 |
